35197-64-9

Basic information

• Product Name: 2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid
• Synonyms: 2-Bromo-4-(1,3-dioxoisoindolin-2-yl);2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid;2-bromo-4-(1,3-dioxoisoindol-2-yl)butanoic acid
• CAS NO: 35197-64-9
• Molecular Formula: C₁₂H₁₀BrNO₄
• Molecular Weight: 312.1161
• Mol File: 35197-64-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid(35197-64-9)
• EPA Substance Registry System: 2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid(35197-64-9)

Safety Data

• Hazardous Substances Data: 35197-64-9(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid is a chemical compound with the molecular formula C11H10BrNO5. It is an organic compound that contains a bromine atom and a carboxylic acid functional group. 2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid is commonly used in organic synthesis and medicinal chemistry for the development of pharmaceutical drugs. It has been studied for its potential therapeutic applications, particularly in the treatment of neurological disorders and cancer. Additionally, it has shown promise as a building block for the synthesis of complex organic molecules. Due to its unique structure and functional groups, 2-Bromo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid is an important compound in the field of organic chemistry and drug discovery.

Upstream product

• 85-44-9 phthalic anhydride 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 108749-42-4 2-amino-4-phthalimido-butyric acid 
• 3130-75-4 4-phthalimidobutyric acid 

Downstream Products

• 21615-25-8 N,N'-dicyclohexyldiamide of phthalic acid 
• 99849-71-5 4-Amino-2-cyclohexylamino-buttersaeure 
• 38228-97-6 N¹,N²-diisopropylphthalamide 
• 19532-96-8 N,N'-dibutylamide of phthalic acid 
• 1369963-04-1 tert-butyl 2-[(4-bromophenyl)(methylsulfonyl)amino]-4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoate 
• 1369963-05-2 tert-butyl 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-[(4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]butanoate 
• 1369962-00-4 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-[(4'-methoxybiphenyl-4-yl)(methylsulfonyl)amino]butanoic acid 
• 1369963-06-3 tert-butyl 2-[biphenyl-4-yl(methylsulfonyl)amino]-4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoate 
• 1369961-98-7 2-[biphenyl-4-yl(methylsulfonyl)amino]-4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoic acid 
• 1621341-94-3 2-bromo-4-(1,3-dioxoisoindolin-2-yl)-N-(4-methylbenzyl)butanamide 
• 1621341-92-1 2-bromo-4-(1,3-dioxoisoindolin-2-yl)-N-(4-fluorobenzyl)butanamide 
• 1621341-90-9 2-bromo-N-(4-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide 
• 1621341-88-5 2-bromo-N-(2-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide 
• 16699-70-0 N-benzyl-2-bromo-4-(1,3-dioxoisoindolin-2-yl)butanamide 

Relevant articles and documents

Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides

Six series of 2-substituted 4-aminobutanamide derivatives were synthesized and evaluated for their ability to inhibit GABA transport proteins mGAT1-4 stably expressed in HEK-293 cell lines. The pIC50 values determined were in the range 4.23-5.23. Two compounds (15b and 15c) were selected for further in vitro studies. These compounds were also subjected to preliminary behavioral studies to evaluate their anticonvulsant, antidepressant-like, and antinociceptive activities in mice. Their influence on motor coordination was also assessed. We report that, among a spectrum of in vivo activities, both 15b and 15c displayed significant activity against pentylenetetrazole (PTZ)-induced seizures.

MATRIX METALLOPROTEINASE INHIBITORS

The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds.

THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS

The present invention relates to compounds with the formula (I), wherein R1, R2, R3, X, and Y are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.